Riitta Lassila

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3310741/publications.pdf

Version: 2024-02-01

79 papers	1,190 citations	19 h-index	477307 29 g-index
82	82	82	1564
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	AFM investigation of APAC (antiplatelet and anticoagulant heparin proteoglycan). Analytical and Bioanalytical Chemistry, 2022, 414, 1029-1038.	3.7	2
2	Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERSâ€IPS study. Journal of Thrombosis and Haemostasis, 2022, 20, 1106-1114.	3.8	5
3	Experience of danaparoid to treat vaccine-induced immune thrombocytopenia and thrombosis, VITT. Thrombosis Journal, 2022, 20, 4.	2.1	6
4	Preoperative oncologic therapy and the prolonged risk of venous thromboembolism in resectable pancreatic cancer. Cancer Medicine, 2022, 11, 1605-1616.	2.8	8
5	Platelet function and filamin A expression in two families with novel <scp>FLNA</scp> gene mutations associated with periventricular nodular heterotopia and panlobular emphysema. American Journal of Medical Genetics, Part A, 2022, , .	1.2	3
6	COVID-19: another reason for anticoagulation in patients with atrial fibrillation. Heart, 2022, 108, 902-904.	2.9	6
7	Thrombosis and Inflammationâ€"A Dynamic Interplay and the Role of Glycosaminoglycans and Activated Protein C. Frontiers in Cardiovascular Medicine, 2022, 9, 866751.	2.4	14
8	Do we need all that emicizumab?. Haemophilia, 2022, 28, .	2.1	7
9	Platelet function testing: Current practice among clinical centres in Northern Europe. Haemophilia, 2022, 28, 642-648.	2.1	5
10	Characterisation of healthcare utilisation and cost of haemophilia care in realâ€life: A 4â€year followâ€up study in Finland. Haemophilia, 2021, 27, e30-e39.	2.1	0
11	Continuous intravenous infusion of enoxaparin controls thrombin formation more than standard subcutaneous administration in critically ill patients. A subâ€study of the ENOKSI thromboprophylaxis RCT. Acta Anaesthesiologica Scandinavica, 2021, 65, 109-115.	1.6	2
12	Whole Blood Thromboelastometry by ROTEM and Thrombin Generation by Genesia According to the Genotype and Clinical Phenotype in Congenital Fibrinogen Disorders. International Journal of Molecular Sciences, 2021, 22, 2286.	4.1	9
13	Treatment outcomes in persons with severe haemophilia B in the Nordic region: The Bâ€NORD study. Haemophilia, 2021, 27, 366-374.	2.1	6
14	Thromboelastometry detects enhancement of coagulation in blood by emicizumab via intrinsic pathway. Haemophilia, 2021, 27, e571-e574.	2.1	5
15	Bleeding phenotype of patients with moderate haemophilia A and B assessed by thromboelastometry and thrombin generation. Haemophilia, 2021, 27, 793-801.	2.1	1
16	Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. Blood Advances, 2021, 5, 2987-3001.	5. 2	11
17	Safety and Functional Pharmacokinetic Profile of APAC, a Novel Intravascular Antiplatelet and Anticoagulant. Journal of Cardiovascular Pharmacology, 2021, 78, 453-462.	1.9	4
18	Hypercholesterolemia and COVID-19: Statins for Lowering the Risk of Venous Thromboembolism. Frontiers in Cardiovascular Medicine, 2021, 8, 711923.	2.4	2

#	Article	IF	CITATIONS
19	COVID-19 adenovirus vaccine triggers antibodies against PF4 complexes to activate complement and platelets. Thrombosis Research, 2021, 208, 129-137.	1.7	12
20	Anaemia and enhancement of coagulation are associated with severe COVID-19 infection. Scandinavian Journal of Clinical and Laboratory Investigation, 2021, 81, 653-660.	1.2	2
21	Platelets compensate for poor thrombin generation in type 3 von Willebrand disease. Platelets, 2020, 31, 103-111.	2.3	10
22	CA 19-9 doubling time in pancreatic cancer as a predictor of venous thromboembolism: a hospital database study. Acta Oncol \tilde{A}^3 gica, 2020, 59, 237-241.	1.8	3
23	Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B – The MoHem study. Haemophilia, 2020, 26, 891-897.	2.1	23
24	Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERSâ€IPS, an international and collaborative crossâ€sectional study. Journal of Thrombosis and Haemostasis, 2020, 18, 2145-2154.	3.8	20
25	COVID-19 and SIC (!). Journal of Vascular Surgery, 2020, 72, 1148-1150.	1.1	1
26	Heparin Dose and Point-of-Care Measurements of Hemostasis in Cardiac Surgery—Results of a Randomized Controlled Trial. Journal of Cardiothoracic and Vascular Anesthesia, 2020, 34, 2362-2368.	1.3	8
27	Differences in the risk of stroke, bleeding events, and mortality between female and male patients with atrial fibrillation during warfarin therapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 29-36.	3.0	15
28	Gain-of-function CEBPE mutation causes noncanonical autoinflammatory inflammasomopathy. Journal of Allergy and Clinical Immunology, 2019, 144, 1364-1376.	2.9	37
29	Management of coagulation factor VIII (FVIII) inhibitors. Thrombosis Research, 2019, 181, S60-S61.	1.7	8
30	Phenotypic characterization of haemophilia B – Understanding the underlying biology of coagulation factor IX. Haemophilia, 2019, 25, 567-574.	2.1	12
31	Intravenous immunoglobulin treatment in a type 3 von Willebrand disease patient with alloantibodies and a lifeâ€threatening gastrointestinal bleed. Haemophilia, 2019, 25, e291-e293.	2.1	1
32	Warfarin dose requirement in patients having severe thrombosis or thrombophilia. British Journal of Clinical Pharmacology, 2019, 85, 1684-1691.	2.4	10
33	Evaluation of a standardized protocol for thrombin generation using the calibrated automated thrombogram: A Nordic study. Haemophilia, 2019, 25, 334-342.	2.1	12
34	Novel Locally Acting Dual Antiplatelet and Anticoagulant (APAC) Targets Multiple Sites of Vascular Injury in an Experimental Porcine Model. European Journal of Vascular and Endovascular Surgery, 2019, 58, 903-911.	1.5	7
35	Cellular Factor XIII, a Transglutaminase in Human Corneal Keratocytes. International Journal of Molecular Sciences, 2019, 20, 5963.	4.1	6
36	Management of coagulation disorders in severe inflammation. HemaSphere, 2019, 3, 95-98.	2.7	2

#	Article	IF	CITATIONS
37	Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report. HemaSphere, 2019, 3, e286.	2.7	43
38	Heparan sulfates are critical regulators of the inhibitory megakaryocyte-platelet receptor G6b-B. ELife, 2019, 8, .	6.0	33
39	Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency. Thrombosis and Haemostasis, 2018, 118, 451-460.	3.4	22
40	The quality of warfarin therapy and CHA2DS2-VASc score associate with the incidence of myocardial infarction and cardiovascular outcome in patients with atrial fibrillation: data from the nationwide FinWAF Registry. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 211-219.	3.0	10
41	Hemostatic profile under fluid resuscitation during rivaroxaban anticoagulation: an in vitro survey. Transfusion, 2018, 58, 3014-3026.	1.6	5
42	Haematopoietic Stem Cell Transplantation in Children Shifts the Coagulation System towards a Pro-Coagulant State. Thrombosis and Haemostasis, 2018, 118, 1390-1396.	3.4	6
43	Dual antiplatelet and anticoagulant (APAC) heparin proteoglycan mimetic with shear-dependent effects on platelet-collagen binding and thrombin generation. Thrombosis Research, 2018, 169, 143-151.	1.7	13
44	Real-world features associated with cancer-related venous thromboembolic events. ESMO Open, 2018, 3, e000363.	4.5	7
45	Preoperative Biomarker Panel, Including Fibrinogen and FVIII, Improves Diagnostic Accuracy for Pancreatic Ductal Adenocarcinoma. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 1267-1275.	1.7	11
46	Prospective Observation on the Use of Von Willebrand Factor (VWF) Concentrates in a Large Cohort of Type 3 Von Willebrand Disease (VWD): Interim (18-months) Analyses on 149 Cases Enrolled into the 3Winters-lps Project. Blood, 2018, 132, 2464-2464.	1.4	0
47	Effects of thromboprophylactic doses of apixaban and rivaroxaban on coagulation and thrombin generation in association with total hip replacement. Journal of Thrombosis and Thrombolysis, 2017, 43, 562-569.	2.1	10
48	Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry. Pharmacoepidemiology and Drug Safety, 2017, 26, 657-665.	1.9	19
49	Factor XIII deficiency enhances thrombin generation due to impaired fibrin polymerization — An effect corrected by Factor XIII replacement. Thrombosis Research, 2017, 149, 56-61.	1.7	17
50	The evolution of the Helsinki frostbite management protocol. Burns, 2017, 43, 1455-1463.	1.9	44
51	Developing the First Recombinant Factor XIII for Congenital Factor XIII Deficiency: Clinical Challenges and Successes. Seminars in Thrombosis and Hemostasis, 2017, 43, 059-068.	2.7	15
52	Dual antiplatelet and anticoagulant APAC prevents experimental ischemia–reperfusion-induced acute kidney injury. Clinical and Experimental Nephrology, 2017, 21, 436-445.	1.6	18
53	Coordinated responses of natural anticoagulants to allogeneic stem cell transplantation and acute GVHD – A longitudinal study. PLoS ONE, 2017, 12, e0190007.	2.5	4
54	Total joint replacement in inhibitor-positive haemophilia: Long-term outcome analysis in fifteen patients. World Journal of Orthopedics, 2017, 8, 777-784.	1.8	2

#	Article	IF	Citations
55	Clinical Use of Factor XIII Concentrates. Seminars in Thrombosis and Hemostasis, 2016, 42, 440-444.	2.7	16
56	Venous thromboembolism after surgical treatment of non-spinal skeletal metastases — An underdiagnosed complication. Thrombosis Research, 2016, 141, 124-128.	1.7	12
57	Platelet Function Tests in Bleeding Disorders. Seminars in Thrombosis and Hemostasis, 2016, 42, 185-190.	2.7	34
58	Coâ€Prescribing of Potentially Interacting Drugs during Warfarin Therapy – A Populationâ€Based Register Study. Basic and Clinical Pharmacology and Toxicology, 2015, 117, 126-132.	2.5	13
59	Implementation of non-vitamin K antagonist oral anticoagulants in daily practice: the need for comprehensive education for professionals and patients. Thrombosis Journal, 2015, 13, 22.	2.1	37
60	Hantavirus infection-induced thrombocytopenia triggers increased production but associates with impaired aggregation of platelets except for collagen. Thrombosis Research, 2015, 136, 1126-1132.	1.7	22
61	From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples. Thrombosis Research, 2015, 136, 154-160.	1.7	20
62	Enhanced thrombin generation and reduced intact protein S in processed solvent detergent plasma. Thrombosis Research, 2015, 135, 167-174.	1.7	17
63	Activation of endothelium, coagulation and fibrinolysis is enhanced and associates with renal anti-neutrophil cytoplasmic antibody-associated vasculitisâ€. Nephrology Dialysis Transplantation, 2015, 30, i53-i59.	0.7	31
64	Mast Cell–Derived Heparin Proteoglycans As a Model for a Local Antithrombotic. Seminars in Thrombosis and Hemostasis, 2014, 40, 837-844.	2.7	21
65	The association of statin use with reduced incidence of venous thromboembolism: a population-based cohort study. BMJ Open, 2014, 4, e005862.	1.9	15
66	The European Haemophilia Network (EUHANET). Blood Transfusion, 2014, 12 Suppl 3, s515-8.	0.4	11
67	Nordic Haemophilia Council's Practical Guidelines on Diagnosis and Management ofvon Willebrand Disease. Seminars in Thrombosis and Hemostasis, 2011, 37, 495-502.	2.7	24
68	Practical Viewpoints on the Diagnosis and Management of Heparin-Induced Thrombocytopenia. Seminars in Thrombosis and Hemostasis, 2011, 37, 328-336.	2.7	22
69	Management Strategies of Stroke and Acute Coronary Syndrome In Von Willebrand Disease and Hemophilia: Experience From a Case Series and a Swiss Survey of Frequencies Blood, 2010, 116, 1406-1406.	1.4	1
70	Adaptation of Coagulation and Fibrinolysis in Allogeneic Stem Cell Transplantation Blood, 2007, 110, 3023-3023.	1.4	0
71	Activation of coagulation and fibrinolysis during reconstructive microsurgery in patients with cancer. Microsurgery, 2001, 21, 208-213.	1.3	33
72	Procoagulant Activity on Platelets Adhered to Collagen or Plasma Clot. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 628-635.	2.4	25

RIITTA LASSILA

#	Article	IF	CITATION
73	Coimmobilized Native Macromolecular Heparin Proteoglycans Strongly Inhibit Platelet-Collagen Interactions in Flowing Blood. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, E113-9.	2.4	17
74	Studies of Adhesion-Dependent Platelet Activation. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 3033-3043.	2.4	42
75	Physical Exertion Induces Thrombin Formation and Fibrin Degradation in Patients With Peripheral Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 244-249.	2.4	75
76	Native Macromolecular Heparin Proteoglycans Exocytosed From Stimulated Rat Serosal Mast Cells Strongly Inhibit Platelet-Collagen Interactions. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 3578-3587.	2.4	51
77	The effect of acetylsalicylic acid on the outcome after lower limb arterial surgery with special reference to cigarette smoking. World Journal of Surgery, 1991, 15, 378-382.	1.6	16
78	Gemfibrozil decreases platelet reactivity in patients with hypercholesterolemia during physical stress. Clinical Pharmacology and Therapeutics, 1988, 43, 302-307.	4.7	18
79	Peripheral Arterial Diseaseâ€"Natural Outcome. Acta Medica Scandinavica, 1986, 220, 295-301.	0.0	46